UOKiK probes software-enabled exchange of strategic information between pharmaceutical wholesalers

Written By

piotr dynowski module
Piotr Dynowski

Partner
Poland

I am a Partner and Co-Head of our Intellectual Property and TMT teams, based in Warsaw.

marcin alberski module
Marcin Alberski

Counsel
Poland

I am a counsel in EU & Competition Law and Tech & Comms team in Warsaw. I specialise in competition law and telecommunications law.

Following the dawn raids conducted in September 2020, the President of the Polish Office for Competition and Consumer Protection (UOKiK) has initiated antitrust proceedings against 10 entities – 8 pharmaceutical wholesalers and 2 software providers.

In its press release of 28 February 2022, UOKiK expresses its view that the 10 entities may have concluded an agreement to exchange competitively sensitive (strategic) information on, inter alia, the price lists used, discounts granted and margins.

UOKiK alleges that pharmaceutical wholesalers have used software installed in pharmacies to obtain access to competitively sensitive information on the prices, discounts and margins of their competitors.

UOKiK did not specify whether the software used for an alleged exchange of information was a standard software offered by the IT providers, or whether it was developed specifically for the purpose of allowing access to competitors’ data. UOKiK also did not comment on the extent to which the software companies were aware of the alleged practice.

The President of UOKiK has stated that the exchange of information between pharmaceutical wholesalers may have restricted competition in the market and resulted in higher prices for consumers in pharmacies.

The allegations concern pharmaceutical wholesalers (Farmacol ITB, Farmacol, Farmacol Serwis, Farmacol-Logistics, Farmateka, Neuca, Polska Grupa Farmaceutyczna, and Świat Zdrowia) and two medical information technology software providers (Kamsoft and SoftForYou).

The practices suspected by the Authority may violate both national and EU legislation. If the allegations are confirmed, the accused companies face penalties of up to 10 per cent of their annual turnover.

Interestingly, this is not the first time when the software used in the pharmaceutical sector was subject to UOKiK’s investigation. The other time it concerned a situation where software was allegedly used to restrict pharmacies’ access to the supply of certain drugs.

The press release of the Polish competition authority is available here (in English)

For more information, please contact Piotr Dynowski and Marcin Alberski.

Visit our Competition & EU homepage

Latest insights

More Insights
featured image

Bird & Bird marks World Children’s Day by announcing its forthcoming Global Comparative Guide to Children in the Digital World

7 minutes Nov 20 2024

Read More
Carabiner

Update: Reform of product liability adopted - New liability and litigation risks for companies!

Nov 19 2024

Read More
The European Commission Modern office buildings in Brussels, Belgium.

VAT in the Digital Age (“ViDA”): prepare your business with Bird & Bird – 10 key insights for success

Nov 15 2024

Read More